Endra Life Sciences Inc (NDRA): They study liver fat which Steatosis. It...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	169
Posts	24034
Boards Moderated	0
Alias Born	05/13/2014

Penny chatter

Re: dndodd post# 266

Wednesday, 06/17/2020 12:16:02 PM

Wednesday, June 17, 2020 12:16:02 PM

They study liver fat which Steatosis. It's a huge market for a non invasive test.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent NDRA News

Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:10:30 PM
ENDRA Life Sciences Announces Reverse Stock Split • Business Wire • 08/16/2024 12:00:00 PM
Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 09:00:03 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:06:44 PM
ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024 • Business Wire • 08/13/2024 08:05:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 01:24:59 PM
ENDRA Life Sciences Announces Leadership Changes • Business Wire • 08/13/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 12:02:42 PM
ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14 • Business Wire • 08/07/2024 12:00:00 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/17/2024 08:16:56 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:16:45 PM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/14/2024 08:01:26 PM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/14/2024 12:00:02 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:00:40 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/05/2024 04:15:12 AM
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering • Business Wire • 06/04/2024 01:21:00 PM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:21:05 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 12:05:32 PM
ENDRA Provides Update Following In-person Meeting with FDA • Business Wire • 05/20/2024 12:00:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:26:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:17:00 PM
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update • Business Wire • 05/14/2024 08:05:00 PM

More NDRA News

InvestorsHub NewsWire

HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM

PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM

VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM

Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM

Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM

POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover